<DOC>
	<DOCNO>NCT00327288</DOCNO>
	<brief_summary>Protocol AMP-010 Phase 1b study imexon plus docetaxel patient previously treat breast cancer , previously treat lung cancer hormone refractory prostate cancer . Docetaxel approve Food Drug Administration ( FDA ) second line therapy cancer . The imexon administer day 1-5 docetaxel day 1 every 3 week cycle . The objective protocol determine high dose imexon give full dose docetaxel , provide information enable design future study focus one specific cancer type .</brief_summary>
	<brief_title>Safety Study Imexon Plus Docetaxel Lung , Breast Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Be diagnose previously treat breast , lung , prostate cancer docetaxel indicate . Prior treatment ; least one prior regimen require . Able perform activity daily live . Off prior cancer therapy least 4 week . If female neither pregnant nursing . Willing use contraceptive prevent pregnancy . No serious illness . No active malignancy . No serious infection . No current drug therapy cancer . Blood count blood chemistry near normal range . Prior radiation permit . Active brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hormone refractory prostate cancer</keyword>
</DOC>